{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-essential-documents-after-trial-ich-e6-section-8”
},
“headline”: “SOP for Essential Documents After Trial (ICH E6 §8)”,
“description”: “This SOP defines the procedures for collecting, filing, and archiving essential documents required after the completion of a clinical trial, in compliance with ICH E6 §8, FDA, EMA, CDSCO, and WHO GCP requirements. It covers trial closeout reports, clinical study reports, IP destruction certificates, financial reconciliations, and archiving processes.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}
Published on 21/12/2025
Standard Operating Procedure for Essential Documents After Trial (ICH E6 §8)
| SOP No. | CR/OPS/078/2025 |
| Supersedes | NA |
| Page No. | 1 of 36 |
| Issue Date | 26/08/2025 |
| Effective Date | 01/09/2025 |
| Review Date | 01/09/2026 |
Purpose
The purpose of this SOP is
Scope
This SOP applies to sponsors, CROs, investigators, QA, and TMF administrators involved in the closeout, filing, and archiving of essential trial documents. It covers site closeout, final trial reporting, investigational product (IP) destruction, financial reconciliation, and TMF/ISF archiving.
Responsibilities
- Sponsor: Ensures all essential documents are filed, reconciled, and archived.
- CRO: May handle closeout activities under sponsor oversight.
- Investigator: Provides final subject-level records and site closeout report.
- QA: Audits TMF and ISF for completeness at closeout.
- TMF Administrator: Reconciles and files documents, coordinates archiving.
- Regulatory Affairs: Submits final reports to authorities and ECs.
Accountability
The sponsor is accountable for the completeness and retention of essential documents after the trial. The PI is accountable for site-level closeout documentation. QA is accountable for verifying inspection readiness before archiving.
Procedure
1. Site Closeout Documentation
1.1 File Site Closeout Visit Report prepared by CRA.
1.2 File Investigator’s Final Report/Letter of Completion to EC/IRB.
1.3 File EC/IRB notification of trial closure.
2. Final Clinical Trial Reports
2.1 File Clinical Study Report (CSR) prepared per ICH E3 guidelines.
2.2 File statistical analysis reports and listings.
2.3 File data transfer certificates and database lock confirmation.
3. Investigational Product Documentation
3.1 File IP accountability reconciliation logs.
3.2 File IP destruction certificates signed by pharmacist and witness.
3.3 File correspondence regarding IP return or destruction.
4. Safety Documentation
4.1 File final SAE/SUSAR listings.
4.2 File final DSUR/PSUR submissions.
4.3 File pharmacovigilance closeout summary.
5. Financial and Administrative Documentation
5.1 File final financial reconciliation records.
5.2 File final CRO/vendor invoices and payment records.
5.3 File insurance documentation covering trial period.
6. Subject Documentation
6.1 File final subject status logs (completed, withdrawn, lost to follow-up).
6.2 File subject compensation/reimbursement records.
7. Archiving
7.1 TMF/ISF must be reconciled and complete before archiving.
7.2 Archive essential documents in secure, access-controlled facility.
7.3 Retain for a minimum of 15 years or per jurisdictional requirement.
7.4 Document archiving in TMF Archiving Log (Annexure-1).
Abbreviations
- SOP: Standard Operating Procedure
- TMF/ISF: Trial Master File / Investigator Site File
- PI: Principal Investigator
- CRA: Clinical Research Associate
- CSR: Clinical Study Report
- IP: Investigational Product
- SAE: Serious Adverse Event
- SUSAR: Suspected Unexpected Serious Adverse Reaction
- DSUR/PSUR: Development Safety Update Report / Periodic Safety Update Report
Documents
- TMF Archiving Log (Annexure-1)
- Site Closeout Checklist (Annexure-2)
- IP Destruction Certificate (Annexure-3)
- Final Subject Status Log (Annexure-4)
- Financial Reconciliation Log (Annexure-5)
References
- ICH E6(R2/R3) – Essential Documents After Trial
- FDA – TMF and Clinical Trial Documentation
- EMA – Post-Trial Documentation Guidance
- CDSCO – Clinical Trial Closure Requirements
- WHO – Archiving and Retention of Essential Documents
Version: 1.0
Approval Section
| Prepared By | Ravi Kumar, TMF Administrator |
| Checked By | Sunita Reddy, QA Officer |
| Approved By | Dr. Anil Sharma, Head Clinical Quality |
Annexures
Annexure-1: TMF Archiving Log
| Date | Trial ID | Archived Location | Responsible | Status |
|---|---|---|---|---|
| 20/09/2025 | CT-2025-01 | Central Archive – Mumbai | TMF Admin | Archived |
Annexure-2: Site Closeout Checklist
| Item | Status | Remarks |
|---|---|---|
| Final Monitoring Visit | Complete | Report filed |
| EC/IRB Notification | Complete | Letter filed |
Annexure-3: IP Destruction Certificate
| Date | Batch No. | Quantity Destroyed | Witness | Signature |
|---|---|---|---|---|
| 21/09/2025 | B001 | 50 units | Sunita Reddy | Signed |
Annexure-4: Final Subject Status Log
| Subject ID | Status | Completion Date | Remarks |
|---|---|---|---|
| SUBJ-301 | Completed | 18/09/2025 | – |
| SUBJ-302 | Withdrawn | 17/09/2025 | Consent withdrawn |
Annexure-5: Financial Reconciliation Log
| Date | Document | Amount | Responsible | Status |
|---|---|---|---|---|
| 22/09/2025 | Site Payment Invoice | ₹50,000 | Finance | Paid |
Revision History
| Revision Date | Revision No. | Revision Details | Reason for Revision | Approved By |
|---|---|---|---|---|
| 26/08/2025 | 00 | Initial version | New SOP creation | Head Clinical Quality |
For more SOPs visit: Pharma SOP